ION expands ETF trading capabilities with Tradeweb integration
Investing.com -- Chinese stem cell drug maker Pollon Life has confidentially filed for a Hong Kong initial public offering that could raise approximately $300 million or more, according to a Bloomberg report on Tuesday.
The company, which is backed by Alibaba Group Holding Ltd. founder Jack Ma’s Yunfeng Capital Co., is said to be working with CCB International Holdings Ltd., China International Capital Corp. and UBS Group AG on the planned listing.
Pollon Life, previously known as Platinum Life Excellence Biotech Co., developed amimestrocel injection, which became the first stem cell drug to receive marketing approval in China at the beginning of 2025.
The report added that deliberations are still ongoing and details such as the final IPO size may change.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.